Changes

no edit summary
Line 364: Line 364:  
'''Mutation:''' FUBP1, CIC, IDH, TERT, NOTCH1, PIK3CA or PIK3R1
 
'''Mutation:''' FUBP1, CIC, IDH, TERT, NOTCH1, PIK3CA or PIK3R1
 
|Activation of MYC pathway is often seen with loss of  9p (CDKN2A/B), and 14q (MAX gene)  and is reported to have a worse prognosis
 
|Activation of MYC pathway is often seen with loss of  9p (CDKN2A/B), and 14q (MAX gene)  and is reported to have a worse prognosis
|PMID:27090007; PMID:26061753; PMID:25263767 PMID:26061754; PMID:24335697; PMID:25664944;PMID:26061753; PMID:26941959; PMID:26824661 PMID:26061751
+
|PMID:27090007; PMID:26061753; PMID:25263767 PMID:26061754; PMID:24335697; PMID:25664944;PMID:26061753; PMID:26941959; PMID:26824661 PMID:26061751
 
|-
 
|-
 
|
 
|
Line 386: Line 386:  
'''Amplification:'''  EGFR, MDM4, MDM2, CDK4, PDGFRA, MET   
 
'''Amplification:'''  EGFR, MDM4, MDM2, CDK4, PDGFRA, MET   
 
|Overall poor prognosis.    Gain of 19q, amplification of EGFR, and homozygous loss of CDKN2A are seen primarily in patients over age 40. Co-gain of 19 and 20 may be associated with longer survival.
 
|Overall poor prognosis.    Gain of 19q, amplification of EGFR, and homozygous loss of CDKN2A are seen primarily in patients over age 40. Co-gain of 19 and 20 may be associated with longer survival.
|PMID:26061754; PMID:25754088; PMID:28535583 PMID:25931051; PMID:26091668; PMID:25461780; PMID:27157931; PMID:25727226; PMID:26061751      
+
|PMID:26061754; PMID:25754088; PMID:28535583 PMID:25931051; PMID:26091668; PMID:25461780; PMID:27157931; PMID:25727226; PMID:26061751
 
|-
 
|-
 
|'''MENINGIOMA'''
 
|'''MENINGIOMA'''
Line 399: Line 399:  
'''Mutation:''' NF2, PI3K, SMO, AKT1, KLF4, TRAF7, TERT, ARID1A   
 
'''Mutation:''' NF2, PI3K, SMO, AKT1, KLF4, TRAF7, TERT, ARID1A   
 
|Array findings characteristic of higher grade tumors when histology supports lower grade may suggest increased likelihood of recurrence.  Polysomy,  particularly involving chromosome 5, are seen in angiomatous meningiomas. LOH 1p and/or LOH 1p/14q correlated with anaplastic transformation.
 
|Array findings characteristic of higher grade tumors when histology supports lower grade may suggest increased likelihood of recurrence.  Polysomy,  particularly involving chromosome 5, are seen in angiomatous meningiomas. LOH 1p and/or LOH 1p/14q correlated with anaplastic transformation.
|PMID:23528542; PMID:27575681; PMID:20015288 PMID:21988727; PMID19918127; PMID:25347344 PMID:23334667; PMID:25963524; PMID:26826201 PMID:28195122; PMID:26323607; PMID:11958368; PMID:25965831; PMID:24536048; PMID:24722350 PMID:12568317; PMID:26771848; PMID:27012381; PMID:27480481; PMID:27624470; PMID:27624470 PMID:27458586; PMID:25347344; PMID:17225936  
+
|PMID:23528542; PMID:27575681; PMID:20015288 PMID:21988727; PMID19918127; PMID:25347344 PMID:23334667; PMID:25963524; PMID:26826201 PMID:28195122; PMID:26323607; PMID:11958368; PMID:25965831; PMID:24536048; PMID:24722350 PMID:12568317; PMID:26771848; PMID:27012381; PMID:27480481; PMID:27624470; PMID:27624470 PMID:27458586; PMID:25347344; PMID:17225936
 
|-
 
|-
 
|
 
|
Line 418: Line 418:  
'''Amplification:''' RPS6K in higher grades, 17q23
 
'''Amplification:''' RPS6K in higher grades, 17q23
 
|Loss of 9p and amplification or gain of 17q23  are more frequent than other abnormalities.  Gain of 1q  is assocociated with a shorter PFS; Loss of 1p, 9p and 10 appear with greater frequency as tumor grade increases.
 
|Loss of 9p and amplification or gain of 17q23  are more frequent than other abnormalities.  Gain of 1q  is assocociated with a shorter PFS; Loss of 1p, 9p and 10 appear with greater frequency as tumor grade increases.
|PMID:23528542; PMID:27575681; PMID:20015288 PMID:21988727; PMID19918127; PMID:25347344 PMID:23334667; PMID:25963524; PMID:26826201 PMID:28195122; PMID:26323607; PMID:11958368; PMID:25965831; PMID:24536048; PMID:24722350 PMID:12568317; PMID:26771848; PMID:27012381; PMID:27480481; PMID:27624470; PMID:27624470 PMID:27458586; PMID:25347344; PMID:17225936  
+
|PMID:23528542; PMID:27575681; PMID:20015288 PMID:21988727; PMID19918127; PMID:25347344 PMID:23334667; PMID:25963524; PMID:26826201 PMID:28195122; PMID:26323607; PMID:11958368; PMID:25965831; PMID:24536048; PMID:24722350 PMID:12568317; PMID:26771848; PMID:27012381; PMID:27480481; PMID:27624470; PMID:27624470 PMID:27458586; PMID:25347344; PMID:17225936
 
|-
 
|-
 
|'''EPENDYMOMA'''<br>
 
|'''EPENDYMOMA'''<br>
Line 448: Line 448:  
|Favorable prognosis
 
|Favorable prognosis
 
|WHO CNS Tumors (2016)<br>
 
|WHO CNS Tumors (2016)<br>
PMID:21959044; PMID:21840481  
+
PMID:21959044; PMID:21840481
 
|-
 
|-
 
|
 
|